Citations (49)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Marc S. Rendell. (2021) Current and emerging gluconeogenesis inhibitors for the treatment of Type 2 diabetes. Expert Opinion on Pharmacotherapy 22:16, pages 2167-2179.
Read now
Read now
Seham Zakaria Nassar, Noha Mohamed Badae & Yasmine Amr Issa. (2020) Effect of amylin on memory and central insulin resistance in a rat model of Alzheimer’s disease. Archives of Physiology and Biochemistry 126:4, pages 326-334.
Read now
Read now
Nicola A. Gillies, Sayali A. Pendharkar, Ruma G. Singh, John A. Windsor, Madhav Bhatia & Maxim S. Petrov. (2017) Fasting levels of insulin and amylin after acute pancreatitis are associated with pro-inflammatory cytokines. Archives of Physiology and Biochemistry 123:4, pages 238-248.
Read now
Read now
Celeste C. L. Quianzon & Issam E. Cheikh. (2012) History of current non-insulin medications for diabetes mellitus. Journal of Community Hospital Internal Medicine Perspectives 2:3.
Read now
Read now
Pasquale J Palumbo & Jonathan M Wert. (2010) Impact of data from recent clinical trials on strategies for treating patients with type 2 diabetes mellitus. Vascular Health and Risk Management 6, pages 17-26.
Read now
Read now
Articles from other publishers (44)
Ying-Ying Yang, Yan-Tao Ren, Meng-Yu Jia, Chen-Yang Bai, Xiu-Ting Liang, Hui-Ling Gao, Man-Li Zhong, Tao Wang & Chuang Guo. (2023) The human islet amyloid polypeptide reduces hippocampal tauopathy and behavioral impairments in P301S mice without inducing neurotoxicity or seeding amyloid aggregation. Experimental Neurology 362, pages 114346.
Crossref
Crossref
Antea DeMarsilis, Niyoti Reddy, Chrysoula Boutari, Andreas Filippaios, Elliot Sternthal, Niki Katsiki & Christos Mantzoros. (2022) Pharmacotherapy of type 2 diabetes: An update and future directions. Metabolism 137, pages 155332.
Crossref
Crossref
Olivia McCarthy, Signe Schmidt, Merete Bechmann Christensen, Stephen C. Bain, Kirsten Nørgaard & Richard Bracken. (2022) The endocrine pancreas during exercise in people with and without type 1 diabetes: Beyond the beta-cell. Frontiers in Endocrinology 13.
Crossref
Crossref
Georgios Karamanakos, Alexander Kokkinos, Maria Dalamaga & Stavros Liatis. (2022) Highlighting the Role of Obesity and Insulin Resistance in Type 1 Diabetes and Its Associated Cardiometabolic Complications. Current Obesity Reports 11:3, pages 180-202.
Crossref
Crossref
Lavinia Boccia, Tito Borner, Misgana Y. Ghidewon, Patricia Kulka, Chiara Piffaretti, Sarah A. Doebley, Bart C. De Jonghe, Harvey J. Grill, Thomas A. Lutz & Christelle Le Foll. (2022) Hypophagia induced by salmon calcitonin, but not by amylin, is partially driven by malaise and is mediated by CGRP neurons. Molecular Metabolism 58, pages 101444.
Crossref
Crossref
Ruksar Salim Damji, Shamiha Chowdhury & Zaib-Un-Nisa Munawar Hussain. 2022. Research Anthology on Recent Advancements in Ethnopharmacology and Nutraceuticals. Research Anthology on Recent Advancements in Ethnopharmacology and Nutraceuticals
872
901
.
Michael K. Danquah & Jaison Jeevanandam. 2022. Emerging Nanomedicines for Diabetes Mellitus Theranostics. Emerging Nanomedicines for Diabetes Mellitus Theranostics
1
31
.
Babak Dehestani, Nicholas RS Stratford & Carel W le Roux. (2021) Amylin as a Future Obesity Treatment. Journal of Obesity & Metabolic Syndrome 30:4, pages 320-325.
Crossref
Crossref
Adrian Vella. 2021. Clinical Dilemmas in Diabetes. Clinical Dilemmas in Diabetes
174
186
.
Ali Ahmadi, Yunes Panahi, Thomas P. Johnston & Amirhossein Sahebkar. (2021) Antidiabetic drugs and oxidized low-density lipoprotein: A review of anti-atherosclerotic mechanisms. Pharmacological Research 172, pages 105819.
Crossref
Crossref
Salome Gamakharia, Christelle Le Foll, Wolfgang Rist, Tamara Baader-Pagler, Angela Baljuls & Thomas A. Lutz. (2021) The calcitonin receptor is the main mediator of LAAMA's body weight lowering effects in male mice. European Journal of Pharmacology 908, pages 174352.
Crossref
Crossref
Malcolm J. Borg, Cong Xie, Christopher K. Rayner, Michael Horowitz, Karen L. Jones & Tongzhi Wu. (2021) Potential for Gut Peptide-Based Therapy in Postprandial Hypotension. Nutrients 13:8, pages 2826.
Crossref
Crossref
Berrin Ergun-Longmire, Ethel Clemente, Patricia Vining-Maravolo, Cheryl Roberts, Koby Buth & Donald E. Greydanus. (2021) Diabetes education in pediatrics: How to survive diabetes. Disease-a-Month 67:8, pages 101153.
Crossref
Crossref
Ammira Al-Shabeeb Akil, Esraa Yassin, Aljazi Al-Maraghi, Elbay Aliyev, Khulod Al-Malki & Khalid A. Fakhro. (2021) Diagnosis and treatment of type 1 diabetes at the dawn of the personalized medicine era. Journal of Translational Medicine 19:1.
Crossref
Crossref
Ruksar Salim Damji, Shamiha Chowdhury & Zaib-Un-Nisa Munawar Hussain. 2021. Treating Endocrine and Metabolic Disorders With Herbal Medicines. Treating Endocrine and Metabolic Disorders With Herbal Medicines
1
31
.
Santwana Padhi, Amit Kumar Nayak & Anindita Behera. (2020) Type II diabetes mellitus: a review on recent drug based therapeutics. Biomedicine & Pharmacotherapy 131, pages 110708.
Crossref
Crossref
R.S. Tavares, S. Escada-Rebelo, M.I. Sousa, A. Silva, J. Ramalho-Santos & S. Amaral. (2019) Can Antidiabetic Drugs Improve Male Reproductive (Dys)Function Associated with Diabetes?. Current Medicinal Chemistry 26:22, pages 4191-4222.
Crossref
Crossref
Kalkena Sivanesam & Niels Andersen. (2019) Pre-structured hydrophobic peptide β-strands: A universal amyloid trap?. Archives of Biochemistry and Biophysics 664, pages 51-61.
Crossref
Crossref
Karen D Corbin, Kimberly A Driscoll, Richard E Pratley, Steven R Smith, David M Maahs & Elizabeth J Mayer-Davis. (2018) Obesity in Type 1 Diabetes: Pathophysiology, Clinical Impact, and Mechanisms. Endocrine Reviews 39:5, pages 629-663.
Crossref
Crossref
Florentina Tofoleanu, Ye Yuan, Frank C. PickardIVIV, Bartłomiej Tywoniuk, Bernard R. Brooks & Nicolae-Viorel Buchete. (2018) Structural Modulation of Human Amylin Protofilaments by Naturally Occurring Mutations. The Journal of Physical Chemistry B 122:21, pages 5657-5665.
Crossref
Crossref
Qiushan Tao, Haihao Zhu, Xi Chen, Robert A. Stern, Neil Kowall, Rhoda Au, Jan Krzysztof Blusztajn & Wei Qiao Qiu. (2018) Pramlintide: The Effects of a Single Drug Injection on Blood Phosphatidylcholine Profile for Alzheimer’s Disease. Journal of Alzheimer's Disease 62:2, pages 597-609.
Crossref
Crossref
Varun Pathak, Peter R. Flatt & Nigel Irwin. (2018) Cholecystokinin (CCK) and related adjunct peptide therapies for the treatment of obesity and type 2 diabetes. Peptides 100, pages 229-235.
Crossref
Crossref
R S Tavares, S Escada-Rebelo, A F Silva, M I Sousa, J Ramalho-Santos & S Amaral. (2018) Antidiabetic therapies and male reproductive function: where do we stand?. Reproduction 155:1, pages R13-R37.
Crossref
Crossref
Vered Wineman-Fisher & Yifat Miller. (2017) Insight into a New Binding Site of Zinc Ions in Fibrillar Amylin. ACS Chemical Neuroscience 8:9, pages 2078-2087.
Crossref
Crossref
Haihao Zhu, Robert A. Stern, Qiushan Tao, Alexandra Bourlas, Maritza D. Essis, Meenakshi Chivukula, James Rosenzweig, Devin Steenkamp, Weiming Xia, Gustavo A. Mercier, Yorghos Tripodis, Martin Farlow, Neil Kowall & Wei Qiao Qiu. (2017) An amylin analog used as a challenge test for Alzheimer's disease. Alzheimer's & Dementia: Translational Research & Clinical Interventions 3:1, pages 33-43.
Crossref
Crossref
Kathrin Herrmann, Ming Zhou, Andrew Wang & Tjerk W. A. de Bruin. (2016) Cardiovascular safety assessment of pramlintide in type 2 diabetes: results from a pooled analysis of five clinical trials. Clinical Diabetes and Endocrinology 2:1.
Crossref
Crossref
Prachi Gupta, Manju Bala, Sanjeev Gupta, Anita Dua, Rajesh Dabur, Elisha Injeti & Ashwani Mittal. (2016) Efficacy and risk profile of anti-diabetic therapies: Conventional vs traditional drugs—A mechanistic revisit to understand their mode of action. Pharmacological Research 113, pages 636-674.
Crossref
Crossref
Vered Wineman-Fisher & Yifat Miller. (2016) Structural Insights into the Polymorphism of Self-Assembled Amylin Oligomers. Israel Journal of Chemistry 56:8, pages 590-598.
Crossref
Crossref
H Zhu, X Wang, M Wallack, H Li, I Carreras, A Dedeoglu, J-Y Hur, H Zheng, H Li, R Fine, M Mwamburi, X Sun, N Kowall, R A Stern & W Q Qiu. (2014) Intraperitoneal injection of the pancreatic peptide amylin potently reduces behavioral impairment and brain amyloid pathology in murine models of Alzheimer’s disease. Molecular Psychiatry 20:2, pages 252-262.
Crossref
Crossref
Erin St. Onge, Shannon A. Miller, Carol Motycka & Adrienne DeBerry. (2015) A Review of the Treatment of Type 2 Diabetes in Children. The Journal of Pediatric Pharmacology and Therapeutics 20:1, pages 4-16.
Crossref
Crossref
Wei Qiao Qiu, Max Wallack, Michael Dean, Elizabeth Liebson, Mkaya Mwamburi & Haihao Zhu. (2014) Association between Amylin and Amyloid-β Peptides in Plasma in the Context of Apolipoprotein E4 Allele. PLoS ONE 9:2, pages e88063.
Crossref
Crossref
Sandra J. Hamilton & Gerald F. Watts. 2014. Lipoproteins in Diabetes Mellitus. Lipoproteins in Diabetes Mellitus
239
278
.
Nitesh D. Kuhadiya, Ritu Malik, Natalie J. Bellini, Jane Lyons Patterson, Andrea Traina, Antoine Makdissi & Paresh Dandona. (2013) Liraglutide as Additional Treatment to Insulin in Obese Patients with Type 1 Diabetes Mellitus. Endocrine Practice 19:6, pages 963-967.
Crossref
Crossref
Luigi F. Meneghini. (2013) Intensifying Insulin Therapy: What Options Are Available to Patients with Type 2 Diabetes?. The American Journal of Medicine 126:9, pages S28-S37.
Crossref
Crossref
George Grunberger. (2013) Novel therapies for the management of type 2 diabetes mellitus: Part 1. Pramlintide and bromocriptine-QR (2型糖尿病治疗新药：第1部分.普兰林肽与溴隐亭-QR). Journal of Diabetes 5:2, pages 110-117.
Crossref
Crossref
Dhiraj G. Kabra, Uma D. Kabra, Matthias H. Tschöp & Susanna Hofmann. 2012. Sleep Loss and Obesity. Sleep Loss and Obesity
203
225
.
Fernando Ovalle. (2011) Cardiovascular Implications of Antihyperglycemic Therapies for Type 2 Diabetes. Clinical Therapeutics 33:4, pages 393-407.
Crossref
Crossref
Mark Stolar. (2011) Addressing Cardiovascular Risk in Patients With Type 2 Diabetes: Focus on Primary Care. The American Journal of the Medical Sciences 341:2, pages 132-140.
Crossref
Crossref
Jonathan R. S. Arch. 2011. Diabetes - Perspectives in Drug Therapy. Diabetes - Perspectives in Drug Therapy
201
255
.
Ziya Kaygisiz, H. Ozden, N. Erkasap, T. Koken, T. Gunduz, M. Ikizler & T. Kural. (2010) Positive inotropic, positive chronotropic and coronary vasodilatory effects of rat amylin: mechanisms of amylin-induced positive inotropy. Acta Physiologica Hungarica 97:4, pages 362-374.
Crossref
Crossref
Harold E. Lebovitz. (2010) Adjunct therapy for type 1 diabetes mellitus. Nature Reviews Endocrinology 6:6, pages 326-334.
Crossref
Crossref
C M Mack, C J Soares, J K Wilson, J R Athanacio, V F Turek, J L Trevaskis, J D Roth, P A Smith, B Gedulin, C M Jodka, B L Roland, S H Adams, A Lwin, J Herich, K D Laugero, C Vu, R Pittner, J R PaternitiJrJr, M Hanley, S Ghosh & D G Parkes. (2009) Davalintide (AC2307), a novel amylin-mimetic peptide: enhanced pharmacological properties over native amylin to reduce food intake and body weight. International Journal of Obesity 34:2, pages 385-395.
Crossref
Crossref
Arpád Dobolyi. (2009) Central amylin expression and its induction in rat dams. Journal of Neurochemistry 111:6, pages 1490-1500.
Crossref
Crossref
Ilene Fennoy. (2009) Pramlintide in Pediatric Type 1 Diabetes. The Journal of Pediatrics 155:3, pages 308-309.
Crossref
Crossref